Full Press Release Details
CHMP Recommends Updating TYSABRI Labeling with anti-JC Virus Antibody Status as a Third Factor to Further Stratify Risk of PML.
BIIB
CHMP Recommends Updating TYSABRI Labeling with anti-JC Virus Antibody Status as a Third Factor to Further Stratify Risk of PML
Key Takeaway: CHMP Recommends Updating TYSABRI Labeling with anti-JC Virus Antibody Status as a Third Factor to Further Stratify Risk of PML
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Alefacept
Phase 3 · Chronic Plaque Psoriasis